ASCA Program Future Outlook for Device Teams

The ASCA program future outlook matters because testing strategy can affect both submission timing and FDA review efficiency. For medical device manufacturers, the practical question is not whether ASCA replaces a complete regulatory strategy. It does not. The question is how FDA’s Accreditation Scheme for Conformity Assessment may continue to influence the selection of test laboratories, the structure of test evidence, and the credibility of declarations used in premarket submissions.

FDA established ASCA to provide a framework through which recognized accreditation bodies accredit testing laboratories for specified device standards and test methods. When an eligible device is tested by an ASCA-accredited laboratory within its approved scope, the manufacturer may submit an ASCA declaration of conformity and the associated test documentation. This framework is intended to give FDA greater confidence that testing was performed by a qualified laboratory under defined conditions.

For product development, regulatory, and quality teams, the program’s value is operational. It can help align testing with recognized standards before a submission is assembled, reduce uncertainty around laboratory qualifications, and support a more disciplined approach to evidence generation.

The most likely direction for the ASCA program is continued emphasis on consistency, traceability, and standards-based evidence. FDA review teams must assess whether a device meets applicable safety and performance expectations. A test report is more useful when its methods, equipment, personnel competence, deviations, and results can be tied clearly to an accredited laboratory scope and an applicable recognized standard.

ASCA supports that objective by creating a defined relationship among FDA, accreditation bodies, test laboratories, and device manufacturers. The program is not a blanket endorsement of every test a laboratory performs. Its value depends on scope. A laboratory must be accredited for the relevant standard and test method, and the test must be performed under the conditions covered by that accreditation.

That distinction will remain important as device technologies and consensus standards evolve. Manufacturers should expect FDA to continue evaluating whether program scopes, eligible standards, and accreditation processes remain appropriate for current regulatory needs. New or revised standards may change what testing is expected for a particular device type. A laboratory’s ASCA scope may also change over time as it adds or modifies accredited capabilities.

The result is clear: ASCA should be considered early in test planning, not treated as a final documentation step after verification work is complete.

Standards Will Continue to Drive Testing Plans

The future of ASCA is closely connected to the standards FDA recognizes and the ways those standards are applied to specific devices. For electrical medical equipment, this may involve IEC 60601-1 and applicable collateral or particular standards. For ultrasound systems, the plan may include acoustic output measurements, thermal and mechanical index calculations, image quality evaluation, and standards-specific performance testing. For endoscopes, patient monitors, ECG equipment, catheters, and physiotherapy systems, the relevant test matrix will depend on intended use, technology, risk controls, and claims.

A recognized standard is not automatically sufficient for every regulatory question. FDA may expect device-specific rationale, supplemental testing, clinical evidence, software documentation, usability validation, or biocompatibility data. Likewise, a passing test result does not establish that the tested configuration represents every commercial variant.

Manufacturers should therefore avoid treating ASCA as a shortcut. It is better viewed as a controlled pathway for producing certain categories of conformity assessment evidence. The strongest submissions connect the applicable standard, device configuration, test protocol, acceptance criteria, deviations, results, and declaration in a coherent package.

Revision Control Will Become More Significant

Standards change, often with transition periods and evolving regulatory expectations. A development team that waits until design verification is nearly complete may find that the selected edition of a standard, test method, or collateral requirement no longer aligns with its intended submission approach.

A practical standards review should occur at several points: during requirements definition, before finalizing verification protocols, after major design changes, and before submission assembly. This review should confirm the FDA recognition status of applicable standards, the laboratory’s current ASCA scope, and whether the selected device model and accessories are adequately represented.

This is especially relevant for platforms with multiple configurations. A power supply change, probe update, enclosure revision, software release, cable substitution, or accessory addition can affect the applicability of prior evidence. Good configuration management prevents a test report from becoming difficult to defend because the tested article no longer matches the submitted device.

What Manufacturers Should Do Now

The ASCA program future outlook supports a disciplined planning model rather than a speculative one. Manufacturers do not need to predict every future FDA policy decision. They do need to control the elements that determine whether test evidence will be usable when needed.

First, identify applicable standards and regulatory evidence requirements while product requirements are still being defined. This permits the engineering team to build testability into the design and reduces the risk of expensive redesign after pre-compliance findings.

Second, qualify the test laboratory against the work actually required. Ask whether the laboratory is accredited for the specific standard or test method, not simply whether it holds a general accreditation. ISO/IEC 17025 accreditation demonstrates competence within a defined scope. FDA ASCA accreditation adds relevance for eligible testing performed under the laboratory’s ASCA-approved scope. Both credentials should be reviewed in relation to the planned work.

Third, define the test article and documentation package before testing begins. The laboratory should receive sufficient information to establish configuration control, including model numbers, software versions, accessories, intended use, operating modes, and any known deviations from a base configuration. Ambiguity at this stage can create report revisions, repeat testing, or questions during regulatory review.

Finally, allow time for technical review. A report should be assessed for completeness, clear methods, traceable instrumentation, acceptance criteria, deviations, observations, and accurate identification of the device tested. Regulatory teams should also verify that declarations, reports, and submission references are consistent with one another.

Where ASCA May Have Limits

ASCA offers meaningful value, but the appropriate use case depends on the device and submission. Some products require testing that falls outside the laboratory’s ASCA scope or outside the program’s eligible standards. Others may involve novel technologies for which consensus standards address only part of the risk profile. In those cases, a manufacturer may need supplemental methods, engineering rationale, bench testing, simulated-use testing, clinical evaluation, or human factors validation.

There is also a commercial trade-off. Selecting a laboratory solely because it is ASCA-accredited may not be sufficient if it lacks the specialized equipment, technical depth, or capacity required for the device. Conversely, a highly specialized laboratory may provide critical testing outside an ASCA scope. The right approach is to match each test activity to the laboratory competence, accreditation scope, schedule, and regulatory purpose.

For complex devices, this may mean using more than one qualified laboratory. The manufacturer remains responsible for integrating the resulting evidence into a consistent submission narrative. That includes showing how safety, performance, usability, and risk management evidence support the same device configuration and intended use.

The Laboratory Relationship Will Matter More

As regulatory submissions become more evidence-driven, manufacturers benefit from involving the testing laboratory before protocols are fixed. Early technical discussion can identify fixture needs, worst-case operating conditions, sample quantities, environmental controls, required documentation, and expected turnaround time. It can also clarify whether a proposed test falls within an accredited scope.

Sigma Scientific Services supports this planning approach through specialized medical device safety and performance testing, including electrical, acoustic, ultrasound, endoscope, materials, physiotherapy, clinical safety, and human factors evaluations. For manufacturers working toward an ASCA-supported submission strategy, the relevant question is whether the required standard and test method fit the laboratory’s current accredited scope and the device’s final configuration.

The most effective next step is to treat ASCA as part of verification planning from the start. When standards selection, laboratory qualification, configuration control, and documentation review are handled before testing begins, the resulting evidence is better positioned to support regulatory decisions when the submission timeline becomes critical.